Xenobiotic cannabinoid CB1/
CB2-receptor agonists appear to possess broad-spectrum
antiemetic activity since they prevent
vomiting produced by a variety of
emetic stimuli including the chemotherapeutic agent
cisplatin,
serotonin 5-HT3-receptor
agonists, dopamine D2/D3-receptor agonists and
morphine, via the stimulation of CB1-receptors. The purpose of this study was to evaluate whether structurally-diverse
cannabinoids [Delta9-
THC, (delta-9-
tetrahydrocannabinol); (Delta8-
THC, delta-8-
tetrahydrocannabinol); WIN55,212-2, (R (+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)), methyl] pyrolol [1,2,3-de]-1,4 benzoxazinyl]-(1-naphthalenyl) methenone
mesylate); and
CP55,940, ((-)-3-[2-hydroxy-4-(1,1-dimethylheptyl]-4-[3-hydroxypropyl]
cyclohexane-1-ol)), can prevent radiation-induced
emesis. Exposure to total body radiation (0, 5, 7.5 and 10 Gy) caused robust
emesis in the least shrew (Cryptotis parva) in a dose-dependent manner (ED50=5.99 (5.77-6.23) Gy) and all animals vomited at the highest tested dose of radiation. In addition, the radiation exposure reduced locomotor behaviors to a significant but mild degree in a non-dose-dependent fashion up to one hour post-treatment. Radiation-induced
emesis (10 Gy) was blocked in a dose-dependent manner by the CB1/
CB2-receptor agonists with the following ID50 potency order:
CP55,940 (0.11 (0.09-0.12) mg/kg)>WIN55,212,2 (3.65 (3.15-4.23) mg/kg)=Delta8-
THC (4.36 (3.05-6.22) mg/kg)>Delta9-
THC (6.76 (5.22-8.75) mg/kg). Although the greater
antiemetic potency and efficacy of Delta8-
THC relative to its isomer Delta9-
THC is unusual as the latter
cannabinoid possesses higher affinity and potency for
cannabinoid receptors in functional assays, the current data support the results of a clinical study in children suggestive of complete protection from
emesis by Delta8-
THC. This effect has not been clinically observed for Delta9-
THC in
cancer patients receiving chemo- or
radiation-therapy.
Cannabinoids prevented the induced
emesis via the stimulation of
cannabinoid CB1-receptors because the CB1 (
SR141716A)--and not the CB2 (
SR144528)--receptor antagonist reversed both the observed reduction in
emesis frequency and shrew
emesis protection afforded by either Delta9-
THC or
CP55,940 against radiation-induced
emesis. These findings further suggest that the least shrew can be utilized as a versatile and inexpensive small animal model to rapidly screen the efficacy of investigational
antiemetics for the prevention of radiation-induced
emesis.